Roche Polymerase Inhibitor Shows Promise In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Ahead of AASLD, Roche’s Senior Medical Director Thommes discusses the firm’s hepatitis C pipeline with “The Pink Sheet” DAILY.
You may also be interested in...
Roche Licenses Metabasis Liver Technology, Collaborates To Develop HCV Drugs
HepDirect allows more potent concentrations of nucleosides in liver, resulting in lower dose requirement.
Roche Licenses Metabasis Liver Technology, Collaborates To Develop HCV Drugs
HepDirect allows more potent concentrations of nucleosides in liver, resulting in lower dose requirement.
Protease Inhibitors Line Up To Challenge Vertex In HCV
In-class skirmish likely as combo therapy evolves, analyst tells “The Pink Sheet” DAILY.